|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1992-1-16
|
|
pubmed:abstractText |
Eighteen patients with advanced renal cancer received a combination of IFN alpha 10 x 10(6) U/m2/Day (D) x 5D followed by Interleukin 2 (IL2) 18 x 10(6) UI/m2/D x 5 D. The median follow-up is 10 months. Four partial responses were observed lasting 7 to 13 months (22.2%). The clinical safety was satisfactory. The survival for responding patients is 12 months (median). The safety of treatment is an argument in favour of future trials in an attempt to demonstrate the benefit of combinations of biomodulators.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0003-4401
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
163-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1746923-Adenocarcinoma,
pubmed-meshheading:1746923-Adult,
pubmed-meshheading:1746923-Aged,
pubmed-meshheading:1746923-Alkaline Phosphatase,
pubmed-meshheading:1746923-Bilirubin,
pubmed-meshheading:1746923-Creatinine,
pubmed-meshheading:1746923-Female,
pubmed-meshheading:1746923-Humans,
pubmed-meshheading:1746923-Interferon-alpha,
pubmed-meshheading:1746923-Interleukin-2,
pubmed-meshheading:1746923-Kidney Neoplasms,
pubmed-meshheading:1746923-Lung Neoplasms,
pubmed-meshheading:1746923-Male,
pubmed-meshheading:1746923-Middle Aged,
pubmed-meshheading:1746923-Nephrectomy,
pubmed-meshheading:1746923-Remission Induction
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
[Interferon and interleukin 2 in metastatic cancer of the kidney. Apropos of 18 cases].
|
|
pubmed:affiliation |
Service d'Oncologie Médicale, Hôpital Avicenne, Bobigny.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
